Adverse events · primary VUR
Antibiotic prophylaxis showed no clear difference in adverse events compared with surveillance or no treatment (moderate certainty).
1 finding from 1 review
Microbial resistance to prophylactic drug: unit of analysis (UTI) · primary VUR
Antibiotic prophylaxis probably leads to higher microbial resistance to prophylactic drug: unit of analysis (UTI) compared with surveillance or no treatment (moderate certainty).
1 finding from 1 review
Recurrence of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower recurrence of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
Incidence rate of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower incidence rate of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
Time to next episode of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower time to next episode of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
Hospital admissions · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis showed no clear difference in hospitalisation compared with no treatment/placebo (low certainty).
1 finding from 1 review
Adverse reactions to treatment Proportion of participants with adverse reactions to treatment · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis showed no clear difference in any adverse reactions compared with no treatment/placebo (low certainty).
1 finding from 1 review
Quality of life · People with recurrent erysipelas or cellulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics may leads to lower pulmonary exacerbations: frequency of one or more hospital admissions compared with placebo (low certainty).
1 finding from 1 review
Quality of life: lost school or working days · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in survival: number of deaths compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Neonatal mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery may leads to lower neonatal mortality compared with standard care (low certainty).
1 finding from 1 review
Early neonatal mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery probably leads to lower early neonatal mortality compared with standard care (moderate certainty).
1 finding from 1 review
Late neonatal mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery probably leads to lower late neonatal mortality compared with standard care (moderate certainty).
1 finding from 1 review
Sepsis‐specific mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery showed no clear difference in sepsis‐specific mortality compared with standard care (low certainty).
1 finding from 1 review
Any adverse events · people with cancer who have febrile neutropenia
It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Surgical site infection · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of surgical site infections (SSIs) before discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review